RENAL IMPAIRMENT IS THE MAJOR TOXICITY OF FOSCARNET SODIUM INJECTION. FREQUENT MONITORING OF SERUM CREATININE, WITH DOSE ADJUSTMENT FOR CHANGES IN RENAL FUNCTION, AND ADEQUATE HYDRATION WITH ADMINISTRATION OF FOSCARNET SODIUM INJECTION, IS IMPERATIVE. (See
SEIZURES, RELATED TO ALTERATIONS IN PLASMA MINERALS AND ELECTROLYTES, HAVE BEEN ASSOCIATED WITH FOSCARNET SODIUM INJECTION TREATMENT. THEREFORE, PATIENTS MUST BE CAREFULLY MONITORED FOR SUCH CHANGES AND THEIR POTENTIAL SEQUELAE. MINERAL AND ELECTROLYTE SUPPLEMENTATION MAY BE REQUIRED.
FOSCARNET SODIUM INJECTION IS INDICATED FOR USE ONLY IN IMMUNOCOMPROMISED PATIENTS WITH CMV RETINITIS AND MUCOCUTANEOUS ACYCLOVIR-RESISTANT HSV INFECTIONS. (See
The chemical name of foscarnet sodium is phosphonoformic acid, trisodium salt.
CMV Retinitis: Foscarnet sodium injection is indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Combination therapy with foscarnet sodium and ganciclovir is indicated for patients who have relapsed after monotherapy with either drug. SAFETY AND EFFICACY OF FOSCARNET SODIUM HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER CMV INFECTIONS (e.g., PNEUMONITIS, GASTROENTERITIS); CONGENITAL OR NEONATAL CMV DISEASE; OR NON-IMMUNOCOMPROMISED INDIVIDUALS.
Mucocutaneous Acyclovir-Resistant HSV Infections: Foscarnet sodium injection is indicated for the treatment of acyclovir-resistant mucocutaneous HSV infections in immunocompromised patients. SAFETY AND EFFICACY OF FOSCARNET SODIUM HAVE NOT BEEN ESTABLISHED FOR TREATMENT OF OTHER HSV INFECTIONS (e.g., RETINITIS, ENCEPHALITIS); CONGENITAL OR NEONATAL HSV DISEASE; OR HSV IN NON-IMMUNOCOMPROMISED INDIVIDUALS.
Published Studies Related to Foscarnet
Antiviral therapeutic efficacy of foscarnet in hepatitis B virus infection. [2005.12]
Foscarnet (PFA), a viral DNA polymerase inhibitor, is a clinical agent for herpes viruses. The goal of the study was to evaluate the therapeutic efficacy of PFA in hepatitis B virus (HBV) infection.
Clinical Trials Related to Foscarnet
Studies of the Ocular Complications of AIDS (SOCA)--Foscarnet-Ganciclovir CMV Retinitis Trial (FGCRT) [Completed]
To evaluate the relative safety and efficacy of ganciclovir and foscarnet as initial
treatment of patients with cytomegalovirus (CMV) retinitis.
An Open Study of Foscarnet Treatment First Episode CMV-Retinitis in AIDS Patients [Completed]
To evaluate the safety and efficacy of foscarnet induction therapy for treatment of AIDS
patients experiencing their first episode of cytomegalovirus (CMV) retinitis. To evaluate
the safety and efficacy of three different foscarnet maintenance therapy regimens. To
determine the pharmacokinetics of intermittent administration of foscarnet with or without
concomitant administration of zidovudine (AZT).
An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies [Completed]
A Study of Foscarnet in the Treatment of Cytomegalovirus (CMV) of the Eyes in Patients With AIDS Who Have Not Had Success With Ganciclovir [Active, not recruiting]
To evaluate the safety and efficacy of foscarnet induction treatment of cytomegalovirus
(CMV) retinitis in AIDS patients who have previously suffered severe dose-limiting
ganciclovir-related myelosuppression, who are ineligible for ganciclovir treatment due to
myelosuppression or who have clearly failed to have a therapeutic response to ganciclovir
therapy. To assess the duration of clinical response. To evaluate the effect on quantitative
CMV cultures of blood and urine. To determine the effect on recovery of HIV p24 antigen
capture direct from plasma.
Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection in Patients With Herpes Zoster [Not yet recruiting]
The purpose of this study is to evaluate the efficacy and safety of Foscarnet Sodium and
Sodium Chloride Injection in patients with herpes zoster, and observe incidence of
Reports of Suspected Foscarnet Side Effects
Encephalitis Cytomegalovirus (8),
Nephropathy Toxic (7),
Neurological Decompensation (4),
Cytomegalovirus Viraemia (3),
Multi-Organ Failure (3),
Pancytopenia (3), more >>
Page last updated: 2006-11-04